Crossmark

Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era

Published Online: 2024-07-31

Published Print: 2024-10

Authors

Vadakkel, Grashma

Eng, Stephen

Proli, Anthony

Ponce, Doris M. https://orcid.org/0000-0002-9422-5766
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | National Institutes of Health (R01 HL164902)
License Information

Text and Data Mining valid from 2024-07-31

Version of Record valid from 2024-07-31
More Information

Article History

Received: 26 January 2024

Revised: 9 July 2024

Accepted: 10 July 2024

First Online: 31 July 2024

Competing interests

: SE has received speaking honorarium from Incyte. DMP has served as an advisory board member for Evive Biotechnology (Shanghai; formerly Generon [Shanghai]), as an advisory board member or consultant for Sanofi, CareDx, Ceramedix, and Incyte, and receives research funding from Incyte and Sanofi. AP is a current employee of Flatiron Health and a current equity holder in Roche. The other authors have no conflicts of interest to declare. Graphic support was provided by ICON PLC and funded by Incyte under the authors’ guidance.

Document is current